Biotech Values

[DewDiligence]

MGNX -17%—phase-3 data from SOPHIA trial came up short of expectations generated by top-line PR in Feb 2019 (#msg-146611035):

Margetuximab improves PFS versus trastuzumab post-trastuzumab and pertuzumab in the SOPHIA phase 3 trial for HER2+ metastatic #BreastCancer . Is there a role for margetuximab within the expanding landscape of therapies including very potent novel ADCs? #ASCO19 #OncoAlert #bcsm pic.twitter.com/pBZlxiGmKD

— Philippe Aftimos, MD  (@aftimosp) June 4, 2019

This was the PR issued last week about today’s webcast:
https://finance.yahoo.com/news/macrogenics-host-conference-call-webcast-203000573.html